Description

Insulin glulisine is a rapid-acting insulin analog developed through recombinant DNA technology. Structural modifications—substituting asparagine with lysine at B3 and lysine with glutamic acid at B29—increase solubility and minimize self-association, enabling fast absorption following subcutaneous injection. Pharmacokinetic studies show peak insulin levels are reached in roughly half the time of regular human insulin and with twice the concentration. Clinically, this analog improves postprandial glucose control while offering flexible dosing around meals (pre- or shortly post-meal). Manufactured under GMP standards with purity ?95%, Insulin glulisine is well-suited for precise glycemic modeling in diabetes research.

Product Specifications

Mechanism of Action & Research Applications

Insulin glulisine activates insulin receptors, enhancing glucose uptake in muscle and fat cells while suppressing hepatic glucose production. Its rapid pharmacodynamics—fast onset and short duration—make it ideal for modeling mealtime insulin dynamics, postprandial glucose excursions, and insulin dosing strategies in diabetes research. The rapid absorption and low self-association also enable operator flexibility in timing insulin administration, offering a robust tool for modeling of basal-bolus regimens and glycemic variability.

Side Effects (For Research Context Only)

In experimental usage, Insulin glulisine’s rapid action can produce hypoglycemia if administered without adequate glucose intake. Other typical reactions include localized injection site variability. Continuous monitoring of glucose levels is essential to avoid undue hypoglycemic events during experimental protocols.

Logistics Transportation

All shipments are fully insured to guarantee safe, secure, and timely delivery. If packages are lost, delayed, or damaged, 100% compensation is provided.

Disclaimer

This product is strictly for laboratory research use only. It is not approved for therapeutic, clinical, veterinary, or diagnostic use.